Literature DB >> 373903

Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine.

E B Doberstyn, P Phintuyothin, S Noeypatimanondh, C Teerakiartkamjorn.   

Abstract

A single oral dose (1.5 g) of mefloquine hydrochloride cured all of 37 patients with falciparum malaria, and a single dose of pyrimethamine (75 mg) plus sulfadoxine (1.5 g) cured 34 of 38 patients. The rates at which parasitaemia and fever abated were similar for the two regimens but mefloquine was associated with a higher incidence of gastrointestinal side effects.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 373903      PMCID： PMC2395771     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


  3 in total

Review 1.  A review of the drug sensitivity of Plasmodium falciparum in Thailand.

Authors:  E J Colwell
Journal:  Southeast Asian J Trop Med Public Health       Date:  1972-06       Impact factor: 0.267

2.  Mefloquine (WR 142,490) in the treatment of human malaria.

Authors:  C M Trenholme; R L Williams; R E Desjardins; H Frischer; P E Carson; K H Rieckmann; C J Canfield
Journal:  Science       Date:  1975-11-21       Impact factor: 47.728

3.  Treatment of falciparum malaria from Vietnam with a phenanthrene methanol (WR 33063) and a quinoline methanol (WR 30090).

Authors:  C J Canfield; A P Hall; B S MacDonald; D A Neuman; J A Shaw
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191
  3 in total
  23 in total

1.  The effect of metoclopramide on mefloquine pharmacokinetics.

Authors:  K Na Bangchang; J Karbwang; D Bunnag; T Harinasuta; D J Back
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

2.  A phase II/III double-blind, dose-finding clinical trial of a combination of mefloquine, sulfadoxine, and pyrimethamine (Fansimef) in falciparum malaria.

Authors:  J M de Souza; U K Sheth; W H Wernsdorfer; P I Trigg; E B Doberstyn
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

3.  High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand.

Authors:  A L Fontanet; D B Johnston; A M Walker; W Rooney; K Thimasarn; D Sturchler; M Macdonald; M Hours; D F Wirth
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

4.  Current concepts in the treatment of malaria in children.

Authors:  B R Thapa; R K Marwaha
Journal:  Indian J Pediatr       Date:  1984 Sep-Oct       Impact factor: 1.967

5.  An open, randomized, phase III clinical trial of mefloquine and of quinine plus sulfadoxine-pyrimethamine in the treatment of symptomatic falciparum malaria in Brazil.

Authors:  J M de Souza; U K Sheth; R M de Oliveira; H Roulet; S D de Souza
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

6.  In vitro susceptibility of Plasmodium falciparum collected from pyrimethamine-sulfadoxine sensitive and resistant areas in Thailand.

Authors:  A Sabchareon; T Chongsuphajaisiddhi; P Attanath; K Kanjanapipatkul; E B Doberstyn; L Suebsaeng
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

7.  A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria.

Authors:  J M Ekue; O O Simooya; U K Sheth; W H Wernsdorfer; E K Njelesani
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

8.  A new in vitro test for pyrimethamine/sulfadoxine susceptibility of Plasmodium falciparum and its correlation with in vivo resistance in Kenya.

Authors:  H C Spencer; W M Watkins; D G Sixsmith; D K Koech; J D Chulay
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

Review 9.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

10.  Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients.

Authors:  F O ter Kuile; F Nosten; C Luxemburger; D Kyle; P Teja-Isavatharm; L Phaipun; R Price; T Chongsuphajaisiddhi; N J White
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.